Pfizer CEO Bourla on Acuitas Deal, mRNA Tech, Djokovic

The transcript discusses Pfizer's strategic focus on partnerships over acquisitions, emphasizing the benefits of collaboration in advancing mRNA technology and other scientific endeavors. It highlights the company's capital allocation priorities, with a focus on staying ahead of COVID-19 and investing in breakthrough science. The potential of mRNA technology in vaccines and other areas like cancer is explored, along with the role of genetic technologies in correcting DNA errors. The conversation also touches on vaccine efficacy, public perception, and the economic aspects of vaccine production.

What challenges does the virus present in terms of vaccine effectiveness?

Explain the role of genetic editing technology in addressing diseases related to DNA mistakes.

How does the production process of vaccines differ from that of oral pill packs in terms of margins?